

Cymevene®

Ganciclovir

1.

DESCRIPTION

1.1. THERAPEUTIC / PHARMACOLOGIC CLASS OF DRUG

Antiviral

ATC code: J05AB06
- 1.2.

TYPE OF DOSAGE FORM

Powder for concentrate for solution for infusion.
- 1.3.

ROUTE OF ADMINISTRATION

Intravenous (IV) infusion.
- 1.4.

STERILE/ RADIOACTIVE STATEMENT

Sterile product.
- 1.5.

QUALITATIVE AND QUANTITATIVE COMPOSITION

Active ingredient: ganciclovir in the form of the sodium salt.

Vials containing dry substance equivalent to 500 mg ganciclovir and approximately 46 mg (2 mEq) sodium.

The vial content is white to off-white solid and the constituted solution in water is colorless to light yellow.

2.

CLINICAL PARTICULARS

2.1. THERAPEUTIC INDICATION(S)

Cymevene vials are indicated for the prevention and treatment of life- or sight-threatening cytomegalovirus (CMV) disease in immunocompromised individuals.

The benefits of Cymevene for CMV prevention in patients with HIV may be limited.

- 2.2.

DOSAGE AND ADMINISTRATION

General

Cymevene must be reconstituted and diluted under the supervision of a healthcare professional and administered as an intravenous infusion (see section 4.2 Special Instructions for Use, Handling and Disposal).

Caution: Cymevene must only be administered by IV infusion over 1 hour, preferably via a plastic cannula, into a vein with adequate blood flow (intramuscular or subcutaneous injection may result in severe tissue irritation due to the high pH (~ 11) of ganciclovir solution. Do not administer by rapid or bolus IV injection because the resulting excessive plasma levels may increase the toxicity of Cymevene (see section 4.2 Special Instructions for Use, Handling and Disposal).

The recommended dosage, frequency, or infusion rates should not be exceeded.

- STANDARD DOSAGE FOR TREATMENT OF CMV DISEASE

Dosage for patients with normal renal function

Induction treatment: 5 mg/kg given as an IV infusion over one hour, every 12 hours for 14–21 days.

Maintenance treatment: For immunocompromised patients at risk of relapse maintenance therapy may be given. 5 mg/kg given as an IV infusion over one hour, once daily on 7 days per week or 6 mg/kg once daily on 5 days per week.

The duration of maintenance treatment should be determined on an individual basis.

- STANDARD DOSAGE FOR PREVENTION OF CMV DISEASE USING PRE-EMPTIVE THERAPY

Dosage for patients with normal renal function

Induction treatment: 5 mg/kg given as an IV infusion over one hour, every 12 hours for 7-14 days.

Maintenance treatment: 5 mg/kg given as an IV infusion over one hour, once daily on 7 days per week or 6 mg/kg once daily on 5 days per week.

The duration of maintenance treatment is based on the risk of CMV disease and should be determined on an individual basis.

- 2.2.1.

Special dosage instructions

Pediatric Patients

Safety and efficacy of ganciclovir in pediatrics have not been established, including use for the treatment of congenital or neonatal CMV infections. The use of Cymevene in children warrants extreme caution due to the potential for long-term carcinogenicity and reproductive toxicity. The benefits of treatment should outweigh the risks (see section 3.2.5 Pharmacokinetics in Special Populations, Pediatric Population).

Geriatric patients
No studies have been conducted in adults older than 65 years of age. Since renal clearance decreases with age, Cymevene should be administered to geriatric patients with special consideration of their renal status (see Table 1 and section 3.2.5 Pharmacokinetics in Special Populations, Geriatric population).

Renal impairment
For patients with renal impairment, the dose of Cymevene should be modified as shown in the table below.

Table 1 Cymevene dosing for renally impaired patients		
CrCl	Induction dose	Maintenance dose
≥ 70ml/ min	5.0 mg/kg q12h	5.0 mg/kg/day
50-69 ml/ min	2.5 mg/kg q12h	2.5 mg/kg/day
25-49 ml/min	2.5 mg/kg/day	1.25 mg/kg/day
10-24 ml/min	1.25 mg/kg/day	0.625 mg/kg/day
< 10 ml/min	1.25 mg/kg 3x/wk after hemodialysis	0.625 mg/kg 3x/wk after hemodialysis

Estimated creatinine clearance can be related to serum creatinine by the following formulae:

For males =
$$\frac{(140 - \text{age [years]}) \times (\text{body weight [kg]})}{(72) \times (0.011 \times \text{serum creatinine } [\mu\text{mol/L}])}$$

For females = 0.85 x male value

As dosage modifications are recommended in patients with renal impairment, serum creatinine or estimated creatinine-clearance levels should be monitored carefully.

Hepatic impairment
The safety and efficacy of Cymevene have not been studied in patients with hepatic impairment (see section 3.2.5 Pharmacokinetics in Special Populations, Hepatic impairment).

- 2.3.

CONTRAINDICATIONS

Cymevene is contraindicated in patients with hypersensitivity to ganciclovir, valganciclovir or to any of the excipients.

- 2.4.

WARNINGS AND PRECAUTIONS

2.4.1. General

Cross hypersensitivity

Due to the similarity of the chemical structure of Cymevene and that of aciclovir and penciclovir, a cross-hypersensitivity reaction between these drugs is possible.

Caution should therefore be used when prescribing Cymevene to patients with known hypersensitivity to acyclovir or penciclovir, (or to their prodrugs, valaciclovir or famciclovir respectively).

Mutagenicity, teratogenicity, carcinogenicity, fertility and contraception
In animal studies, ganciclovir was found to be mutagenic, teratogenic, carcinogenic and to impair fertility. Cymevene should therefore be considered a potential teratogen and carcinogen in humans with the potential to cause birth defects and cancers. Prior to initiation of ganciclovir treatment, patients should be advised of the potential risks to the fetus and to use contraceptive measures. Based on clinical and nonclinical studies, Cymevene may cause temporary or permanent inhibition of spermatogenesis (see section 2.5.1 Females and Males of Reproductive Potential, 2.5.2 Pregnancy, 2.5.3 Lactation, 2.6 Undesirable effects, 3.3 Nonclinical Safety and 4.2 Special Instructions for Use, Handling and Disposal).

Myelosuppression
Cymevene should be used with caution in patients with pre-existing hematological cytopenia or a history of drug-related hematological cytopenia and in patients receiving radiotherapy.

Severe leukopenia, neutropenia, anemia, thrombocytopenia, pancytopenia, bone marrow failure and aplastic anemia have been observed in patients treated with Cymevene. Therapy should not be initiated if the absolute neutrophil count is less than 500 cells/μL or the platelet count is less than 25,000 cells/μL or the hemoglobin is less than 8 g/dL (see section 2.6 Undesirable Effects).

It is recommended that complete blood counts including platelet counts be monitored in all patients during therapy, particularly in patients with renal impairment (see section 2.4.4 Laboratory Tests).

In patients with severe leukopenia, neutropenia, anemia and/or thrombocytopenia, treatment with hematopoietic growth factors and/or the interruption of therapy is recommended (see section 2.6 Undesirable Effects).

Use with other medicines
Seizures have been reported in patients taking imipenem-cilastatin and ganciclovir. Cymevene should not be used concomitantly with imipenem-cilastatin unless the potential benefits outweigh the potential risks (see section 2.8 Interactions with other Medicinal Products and other Forms of Interactions).

Zidovudine and Cymevene each have the potential to cause neutropenia and anemia. Some patients may not tolerate concomitant therapy at full dosage (see section 2.8 Interactions with other Medicinal Products and other Forms of Interactions).

Didanosine plasma concentrations may increase during concomitant use with Cymevene; therefore, patients should be closely monitored for didanosine toxicity (see section 2.8 Interactions with other Medicinal Products and other Forms of Interactions).

Concomitant use of other drugs that are known to be myelosuppressive or associated with renal impairment with Cymevene may result in added toxicity (see section 2.8 Interactions with other Medicinal Products and other Forms of Interactions).

- 2.4.2.

Drug Abuse and Dependence

No information is available for drug abuse and dependence with Cymevene.

- 2.4.3.

Ability to Drive and Use Machines

No studies on the effect on the ability to drive and use machines have been performed. Based on the adverse reaction profile, ganciclovir may have a minor influence on the ability to drive and use machines. Adverse reactions, for example seizures, dizziness and confusion may occur in patients receiving Cymevene (see section 2.6 Undesirable Effects). If they occur, such effects may affect tasks requiring alertness including the patient's ability to drive and operate machinery.

- 2.5.

USE IN SPECIAL POPULATIONS

2.5.1. Females and Males of Reproductive Potential

Fertility

In animal studies ganciclovir was found to impair fertility (see section 3.3.3 Impairment of Fertility). In a clinical study renal transplant patients receiving Valcyte (which is a pro-drug of Cymevene) for CMV prophylaxis for up to 200 days were compared to an untreated control group. Spermatogenesis was inhibited during treatment with Valcyte. At follow-up, approximately six months after treatment discontinuation, the mean sperm density in treated patients was comparable to that observed in the untreated control group. In Valcyte treated patients, all patients with normal sperm density (n=7) and 8/13 patients with low sperm density at baseline, recovered to normal counts after treatment cessation. In the control group, all patients with normal sperm density (n=6) and 2/4 patients with low sperm density at baseline, had normal density at the end of follow-up.

Contraception
Women of reproductive potential should be advised to use effective contraception during and for at least 30 days after treatment. Sexually active men are recommended to use condoms during and for at least 90 days after cessation of treatment with Cymevene, unless it is certain that the female partner is not at risk of becoming pregnant (see sections 2.4.1 Warnings and Precautions, General, Mutagenicity, teratogenicity, carcinogenicity, fertility and contraception and 3.3.4 Reproductive Toxicity).

- 2.5.2.

Pregnancy

In animal studies ganciclovir was associated with reproductive toxicity and teratogenicity (see section 3.3.3 Impairment of Fertility and 3.3.4 Reproductive toxicity).

The safety of Cymevene in pregnant women has not been established. However, ganciclovir readily diffuses across the human placenta. The use of Cymevene should be avoided in pregnant women unless the benefit to the mother outweighs the potential risk to the fetus.

The safe use of Cymevene during labor and delivery has not been established.

- 2.5.3.

Lactation

Peri- and postnatal development has not been studied with ganciclovir but the possibility of ganciclovir being excreted in breast milk and causing

serious adverse reactions in the nursing infant cannot be discounted. Human data are not available but animal data indicates that ganciclovir is excreted in the milk of lactating rats. Therefore, a decision should be made to discontinue the drug or discontinue nursing taking into consideration the potential benefit of Cymevene to the nursing mother.

- 2.5.4.

Pediatric Use

See section 2.2.1 Special Dosage Instructions and 3.2.5 Pharmacokinetics in Special Populations.

- 2.5.5.

Geriatric Use

See section 2.2.1 Special Dosage Instructions and 3.2.5 Pharmacokinetics in Special Populations.

- 2.5.6.

Renal Impairment

In patients with impaired renal function, dosage adjustments based on creatinine clearance are required (see section 2.2.1 Special Dosage Instructions and 3.2.5 Pharmacokinetics in Special Populations).

- 2.5.7.

Hepatic Impairment

The safety and efficacy of Cymevene have not been studied in patients with hepatic impairment (see section 2.2.1 Special Dosage Instructions and 3.2.5 Pharmacokinetics in Special Populations).

- 2.6.

UNDESIRABLE EFFECTS

2.6.1. Clinical Trials

Valganciclovir is a pro-drug of ganciclovir, and adverse reactions associated with valganciclovir can be expected to occur with ganciclovir. Therefore, adverse drug reactions reported with IV or oral ganciclovir (no longer available) or with valganciclovir are included in the table of adverse reactions (see Table 2).

In patients treated with ganciclovir/valganciclovir the most serious and frequent adverse drug reactions are hematological reactions and include neutropenia, anemia and thrombocytopenia.

The frequencies presented in the table of adverse reactions are derived from a pooled population of HIV-infected patients (n=1704) receiving maintenance therapy with ganciclovir (GAN1697, GAN1653, GAN2304, GAN1774, GAN2226, AVI034, GAN041) or valganciclovir (WV15376, WV15705). Exception is made for agranulocytosis, granulocytopenia and anaphylactic reaction; the frequencies of which are derived from post-marketing experience. Frequencies are presented as percentages and as CIOMS frequency categories defined as very common (≥ 1/10), common (≥ 1/100 to < 1/10), uncommon (≥ 1/1,000 to < 1/100), rare (≥ 1/10,000 to < 1/1,000) and very rare (< 1/10,000).

The overall safety profile of ganciclovir/valganciclovir is consistent in HIV and transplant populations except that retinal detachment has only been reported in HIV patients with CMV retinitis. However, there are some differences in the frequency of certain reactions. Intravenous ganciclovir is associated with a lower risk of diarrhea compared to oral valganciclovir. Pyrexia, candida infections, depression, severe neutropenia (ANC <500μL) and skin reactions are reported more frequently in patients with HIV. Renal and hepatic dysfunction is reported more frequently in organ transplant recipients.

Table 2 Frequency of Ganciclovir/Valganciclovir ADRs Reported in HIV Patients Receiving Maintenance Therapy (n=1704)		
ADR (MedDRA) System Organ Class	Percentage	Frequency Category
Infections and infestations:		
Candida infections including oral candidiasis	22.42%	Very common
Upper respiratory tract infection	16.26%	
Sepsis	6.92%	Common
Influenza	3.23%	
Urinary tract infection	2.35%	
Cellulitis	1.47%	
Blood and lymphatic disorders:		
Neutropenia	26.12%	Very common
Anemia	19.89%	
Thrombocytopenia	7.34%	Common
Leukopenia	3.93%	
Pancytopenia	1.06%	
Bone marrow failure	0.29%	Uncommon
Aplastic anemia	0.06%	
Aggranulocytosis*	0.02%	Rare
Granulocytopenia*	0.02%	
Immune system disorders:		
Hypersensitivity	1.12%	Common
Anaphylactic reaction*	0.02%	Rare
Metabolic and nutrition disorders:		
Decreased appetite	12.09%	Very common
Weight decreased	6.46%	
Psychiatric disorders:		
Depression	6.69%	Common
Confusional state	2.99%	
Anxiety	2.64%	
Agitation	0.59%	Uncommon
Psychotic disorder	0.23%	
Thinking abnormal	0.18%	
Hallucinations	0.18%	
Nervous system disorders:		
Headache	17.37%	Very common
Insomnia	7.22%	
Neuropathy peripheral	6.16%	Common
Dizziness	5.52%	
Paraesthesia	3.58%	
Hypoaesthesia	2.58%	
Seizures	2.29%	
Dysgeusia (taste disturbance)	1.35%	
Tremor	0.88%	
Eye disorders:		
Visual impairment	7.10%	Common
Retinal detachment**	5.93%	
Vitreous floaters	3.99%	
Eye pain	2.99%	
Conjunctivitis	1.58%	
Macular edema	1.06%	
Ear and labyrinth disorders:		
Ear pain	1.17%	Common
Deafness	0.65%	Uncommon
Cardiac disorders:		
Arrhythmia	0.47%	Uncommon
Vascular disorders:		
Hypotension	2.05%	Common
Respiratory, thoracic and mediastinal disorders:		

Cough	18.31%	Very common
Dyspnoea	11.80%	
Gastrointestinal disorders:		
Diarrhea	34.27%	Very common
Nausea	26.35%	
Vomiting	14.85%	
Abdominal pain	10.97%	
Dyspepsia	4.81%	Common
Flatulence	4.58%	
Abdominal pain upper	4.58%	
Constipation	3.70%	
Mouth ulceration	3.17%	
Dysphagia	2.93%	
Abdominal distention	2.41%	
Pancreatitis	1.64%	
Hepato-biliary disorders:		
Blood alkaline phosphatase increased	3.58%	Common
Hepatic function abnormal	3.23%	
Aspartate aminotransferase increased	1.88%	
Alanine aminotransferase increased	1.23%	
Skin and subcutaneous tissues disorders:		
Dermatitis	11.80%	Very common
Night sweats	7.92%	Common
Pruritus	4.58%	
Rash	2.52%	
Alopecia	1.29%	
Dry skin	0.94%	Uncommon
Urticaria	0.70%	
Musculo-skeletal and connective tissue disorders:		
Back pain	4.46%	Common
Myalgia	3.52%	
Arthralgia	3.35%	
Muscle spasms	2.99%	
Renal and urinary disorders:		
Renal impairment	2.52%	Common
Creatinine clearance renal decreased	2.35%	
Blood creatinine increased	1.88%	
Renal failure	0.76%	Uncommon
Hematuria	0.70%	
Reproductive system and breast disorders:		
Infertility male	0.23%	Uncommon
General disorders and administration site conditions:		
Pyrexia	33.51%	Very common
Fatigue	18.96%	
Injection site reaction	6.98%	Common
Pain	5.81%	
Chills	5.40%	
Malaise	2.11%	
Asthenia	2.00%	
Chest pain	0.88%	Uncommon

** The frequencies of these adverse reactions are derived from post-marketing experience.*

*** Retinal detachment has only been reported in studies in HIV patients treated with Cymevene for CMV retinitis.*

Description of selected adverse reactions

Neutropenia

The risk of neutropenia is not predictable on the basis of the number of neutrophils before treatment. Neutropenia usually occurs during the first or second week of induction therapy. The cell count usually normalizes within 2 to 5 days after discontinuation of the drug or dose reduction (see section 2.4 Warnings and Precautions).

Thrombocytopenia

Patients with low baseline platelet counts (< 100,000 /µL) have an increased risk of developing thrombocytopenia. Patients with iatrogenic immunosuppression due to treatment with immunosuppressive drugs are at greater risk of thrombocytopenia than patients with HIV (see section 2.4 Warnings and Precautions). Severe thrombocytopenia may be associated with potentially life-threatening bleeding.

Laboratory Abnormalities

Laboratory abnormalities in HIV infected patients

Laboratory abnormalities reported from three clinical trials in HIV infected patients receiving intravenous ganciclovir as maintenance treatment for CMV retinitis are listed below in Table 3. One hundred seventy-nine patients were eligible for the laboratory abnormality analysis.

Table 3 Laboratory abnormalities	
Laboratory abnormalities	N=179
Neutropenia (ANC/mm ³)	
< 500	25.1%
500 - <750	14.3%
750 - < 1000	26.3%
Anemia (hemoglobin g/dl)	
< 6.5	4.6%
6.5 - < 8.0	16.0%
8.0 - < 9.5	25.7%
Thrombocytopenia (platelets/mm ³)	
< 25,000	2.9%
25,000 - < 50,000	5.1%
50,000 - < 100,000	22.9%
Serum creatinine (mg/dl)	
> 2.5	1.7%
> 1.5 – 2.5	13.9%

2.6.2. Postmarketing Experience

Safety reports from the postmarketing setting are consistent with safety data from clinical trials with ganciclovir and valganciclovir (see section 2.6.1 Undesirable Effects – Table 2).

2.7. OVERDOSAGE

Overdose experience with intravenous ganciclovir

Reports of overdoses with intravenous ganciclovir, some with fatal outcomes, have been received from clinical trials and during post-marketing experience. In some of these cases no adverse events were reported. The majority of patients experienced one or more of the following adverse events:

- Hematological toxicity:* myelosuppression including pancytopenia, bone marrow failure, leukopenia, neutropenia, granulocytopenia
- Hepatotoxicity:* hepatitis, liver function disorder
- Renal toxicity:* worsening of hematuria in a patient with preexisting renal impairment, acute kidney injury, elevated creatinine
- Gastrointestinal toxicity:* abdominal pain, diarrhea, vomiting
- Neurotoxicity:* generalized tremor, seizure

Hemodialysis and hydration may be of benefit in reducing blood plasma levels in patients who receive an overdose of oral ganciclovir (see section 3.2.5 Pharmacokinetics in Special Populations).

2.8. INTERACTIONS WITH OTHER MEDICINAL PRODUCTS AND OTHER FORMS OF INTERACTION

Imipenem-cilastatin

Convulsions have been reported in patients who received ganciclovir and imipenem-cilastatin concomitantly and a pharmacodynamic interaction between these two drugs cannot be discounted. These drugs should not be used concomitantly unless the potential benefits outweigh the risks (see section 2.4.1 Warnings and Precautions, General, Use with Other Medicines).

Potential drug interactions

Toxicity may be enhanced when ganciclovir is co-administered with other drugs known to be myelosuppressive or associated with renal impairment This includes nucleoside analogues (e.g. zidovudine, didanosine, stavadine) immunosuppressants (e.g. ciclosporin, tacrolimus, mycophenolate mofetil), antineoplastic agents (e.g. doxorubicin, vincristine, vinblastine, hydroxyurea), and anti-infectives (e.g. trimethoprim/sulphonamides, dapsone, amphotericin B, flucytosine, pentamidine). Therefore, these drugs should only be considered for concomitant use with ganciclovir if the potential benefits outweigh the potential risks (see 2.4.1 Warnings and Precautions, General, Use with Other Medicines).

Zidovudine

Both zidovudine and Cymevene have the potential to cause neutropenia and anemia, a pharmacodynamic interaction may occur during concomitant administration of these drugs, some patients may not tolerate concomitant therapy at full dosage (see section 2.4.1 Warnings and Precautions, General, Use with Other Medicines).

Didanosine

Didanosine plasma concentrations were found to be consistently raised when given with IV ganciclovir. At intravenous doses of 5 and 10 mg/kg/day, an increase in the AUC of didanosine ranging from 38 - 67% has been observed confirming a pharmacokinetic interaction during the concomitant administration of these drugs. There was no significant effect on ganciclovir concentrations. Patients should be closely monitored for didanosine toxicity (e.g. pancreatitis) (see 2.4.1 Warnings and Precautions, General, Use with Other Medicines).

Probenecid

Probenecid given with oral ganciclovir resulted in statistically decreased renal clearance of ganciclovir (20%) leading to statistically significant increased exposure (40%). These changes were consistent with a mechanism of interaction involving competition for renal tubular excretion. Therefore patients taking probenecid and Cymevene should be closely monitored for ganciclovir toxicity.

3. PHARMACOLOGICAL PROPERTIES AND EFFECTS

3.1. PHARMACODYNAMIC PROPERTIES

3.1.1. Mechanism of Action

Ganciclovir is a synthetic analogue of 2'-deoxyguanosine which inhibits replication of herpes viruses in vitro and in vivo. Sensitive human viruses include human cytomegalovirus (HCMV), herpes-simplex virus-1 and -2 (HSV-1 and HSV-2), human herpes virus -6, -7 and -8 (HHV-6, HHV-7, HHV-8), Epstein-Barr virus (EBV), varicella-zoster virus (VZV) and hepatitis B virus. However, clinical studies have been limited to assessment of efficacy in patients with CMV infection.

In CMV infected cells ganciclovir is initially phosphorylated to ganciclovir monophosphate by the viral protein kinase, UL97. Further phosphorylation occurs by several cellular kinases to produce ganciclovir triphosphate, which is then slowly metabolised intracellularly. This has been shown to occur in HSV- and HCMV-infected cells with half-lives of 18 and between 6 and 24 hours respectively after removal of extracellular ganciclovir. As the phosphorylation is largely dependent on the viral kinase, phosphorylation of ganciclovir occurs preferentially in virus-infected cells.

The virustatic activity of ganciclovir is due to the inhibition of viral DNA synthesis by: (1) competitive inhibition of incorporation of deoxyguanosine triphosphate into DNA by DNA polymerase, and (2) incorporation of ganciclovir triphosphate into viral DNA causing termination of, or very limited, viral DNA elongation.

Typical anti-viral IC₅₀ against CMV *in vitro* is in the range 0.08 µM (0.02 µg/mL) to 14 µM (3.5 µg/mL).

3.1.2. Clinical / Efficacy

No text on clinical studies.

Viral resistance

Viruses resistant to ganciclovir can arise after chronic dosing with ganciclovir or valganciclovir by selection of mutations in either the viral kinase gene (UL97) responsible for ganciclovir monophosphorylation or the viral polymerase gene (UL54). UL97 mutations arise earlier and more frequently than mutations in UL54. Virus containing mutations in the UL97 gene is resistant to ganciclovir alone, with M460V/I, H520Q, C592G, A594V, L595S, C603W being the most frequently reported ganciclovir resistance-associated substitutions. Mutations in the UL54 gene may show cross-resistance to other antivirals targeting the viral polymerase, and vice versa. Amino acid substitutions in UL54 conferring cross-resistance to ganciclovir and cidofovir are generally located within the exonuclease domains and region V, however amino acid substitutions conferring cross resistance to foscarnet are diverse, but concentrate at and between regions II (codon 696-742) and III (codon 805-845). The possibility of viral resistance should be considered in patients who repeatedly show poor clinical response or experience continuous viral excretion during treatment

3.1.3. Immunogenicity

Not applicable.

3.2. PHARMACOKINETIC PROPERTIES

The pharmacokinetics of IV ganciclovir is linear over the range of 1.6 - 5.0 mg/kg.

The systemic exposure (AUC_{0-∞}) reported following dosing with a single 1-hour IV infusion of 5 mg/kg ganciclovir in adult liver transplant patients was on average 50.6 µg.h/mL (CV% 40). In this patient population peak plasma concentration (C_{max}) was on average 12.2 µg.h/mL (CV% 24).

3.2.1. Absorption

Not applicable.

3.2.2. Distribution

For IV ganciclovir, the volume of distribution is correlated with body weight with values for the steady state volume of distribution ranging from 0.54 to 0.87 L/kg. Ganciclovir penetrates the cerebrospinal fluid, and diffuses across the placenta. Binding to plasma proteins was 1–2% over ganciclovir concentrations of 0.5 and 51 µg/ml.

3.2.3. Metabolism

Ganciclovir is not metabolized to a significant extent.

3.2.4. Elimination

Renal excretion of unchanged drug by glomerular filtration and tubular secretion is the major route of elimination of ganciclovir. In patients with normal renal function, greater than 90% of IV administered ganciclovir was recovered unmetabolized in the urine within 24 hours.

In patients with normal renal function, systemic clearance ranged from 2.64 ± 0.38 ml/min/kg (N=15) to 4.52 ± 2.79 ml/min/kg (N= 6) and renal clearance ranged from 2.57± 0.69 ml/min/kg (N=15) to 3.48 ± 0.68 ml/min/kg (N= 20), corresponding to 90–101% of administered ganciclovir. Half-lives in patients without renal impairment ranged from 2.73 ±1.29 (N= 6) to 3.98 ±1.78 hours (N= 8).

3.2.5. Pharmacokinetics in special populations

Pediatric population

Ganciclovir pharmacokinetics were studied in 27 neonates aged 2 to 49 days at intravenous doses of 4 mg/kg (N=14) and 6 mg/kg (N=13). Mean C_{max} was 5.5 ± 6 µg/ml and 7.0 ±1.6 µg/ml the lower and higher dose levels respectively. Mean values for V_{ss} (0.7 l/kg) and systemic clearance (3.15 ± 0.47 ml/min/kg at 4 mg/kg and 3.55 ± 0.35 ml/min/kg at 6 mg/kg) were comparable to those observed in adults with normal renal function.

Ganciclovir pharmacokinetics were also studied in 10 children with normal renal function, aged 9 months to 12 years. The pharmacokinetic characteristics of ganciclovir were the same after single and multiple (q12h) IV doses (5 mg/kg). Exposure as measured by mean AUC_∞ on days 1 and 14 were 19.4 ±7.1 and 24.1±14.6 µg·h/ml respectively and the corresponding C_{max} values were 7.59 ± 3.21 (day 1) and 8.31± 4.9 µg/ml (day 14). This range of exposure is comparable to that observed in adults. The steady state volume of distribution after a single dose on day 1 and at the end of the repeat dose period (day 14) was 0.68 ± 0.20 l/kg. Systemic clearance for the same study days was 4.66 ±1.72 (day 1) and 4.86 ± 2.96 ml/min/kg (day 14). The respective mean values for renal clearance (0–12 h) were 3.49 ± 2.40 on day 1 and 3.49 ±1.19 ml/min/kg on day 14. The corresponding mean values for the half-life were 2.49 ± 0.57 (day 1) and 2.22 ± 0.76 h (day 14). The pharmacokinetics of ganciclovir from this study were consistent with those in neonates and adults.

Geriatric population

No ganciclovir pharmacokinetic studies have been conducted in adults older than 65 years of age. However, because ganciclovir is mainly renally excreted and since renal clearance decreases with age, a decrease in ganciclovir total body clearance and prolongation of ganciclovir elimination half-life can be anticipated in the elderly (see section 2.2.1 Special Dosage Instructions, Geriatric patients).

Renal impairment

The total body clearance of ganciclovir is linearly correlated with creatinine clearance. In patients with mild, moderate, and severe renal impairment, mean systemic clearances of 2.1, 1.0 and 0.3 mL/min/kg were observed. Patients with renal impairment show an increased elimination half-life. In patients with severe renal impairment elimination half-life was increased by 10-fold (see section 2.2.1 Special Dosage Instructions, Renal impairment).

Patients undergoing hemodialysis

Plasma concentrations of ganciclovir are reduced by about 50% during a 4hour hemodialysis session (see section 2.7 Overdose).

During intermittent hemodialysis, estimates for the clearance of ganciclovir ranged from 42 to 92 mL/min, resulting in intra-dialytic half-lives of 3.3 to 4.5 hours. Estimates of ganciclovir clearance for continuous dialysis were lower (4.0 to 29.6 mL/min) but resulted in greater removal of ganciclovir over a dose interval. For intermittent hemodialysis, the fraction of ganciclovir removed in a single dialysis session varied from 50 - 63%.

Hepatic impairment

No pharmacokinetic study has been conducted and no population PK data were collected in patients with hepatic impairment undergoing ganciclovir therapy. Hepatic impairment is not anticipated to affect the pharmacokinetics of ganciclovir since ganciclovir is excreted renally (see section 3.2.5 Pharmacokinetics properties, Elimination).

3.3. NONCLINICAL SAFETY DATA

3.3.1. Carcinogenicity

Ganciclovir was mutagenic in mouse lymphoma cells and clastogenic in mammalian cells. Such results are consistent with the positive mouse carcinogenicity study with ganciclovir. Ganciclovir is a potential carcinogen.

3.3.2. Genotoxicity

Ganciclovir was mutagenic in mouse lymphoma cells and clastogenic in mammalian cells.

3.3.3. Impairment of Fertility

Ganciclovir causes impaired fertility and teratogenicity in animals (see section 2.4 Warnings and Precautions).

Based upon animal studies where aspermia was induced at ganciclovir systemic exposures below therapeutic levels, it is considered likely that ganciclovir could cause temporary or permanent inhibition of human spermatogenesis (see section 2.5.1 Females and Males of Reproductive Potential, Fertility).

3.3.4. Reproductive toxicity

Ganciclovir causes teratogenicity in animals.

4. PHARMACEUTICAL PARTICULARS

4.1. STORAGE

This medicine should not be used after the expiry date (EXP) shown on the pack. See also outer pack for storage remark.

Shelf-life and storage of the reconstituted solution

Reconstituted solution in the vial is stable at 25°C for 12 hours. Do not refrigerate or freeze (see section 4.2 Special Instructions for Use, Handling and Disposal).

4.2. SPECIAL INSTRUCTIONS FOR USE, HANDLING AND DISPOSAL

Caution should be exercised in the handling of Cymevene.

Since Cymevene is considered a potential teratogen and carcinogen in humans, caution should be observed in its handling (see section 2.4 Warnings and Precautions). Avoid inhalation or direct contact of the powder contained in Cymevene vials or direct contact of the reconstituted solution with the skin or mucous membranes. Cymevene solutions are alkaline (pH ~11). If such contact occurs, wash thoroughly with soap and water, rinse eyes thoroughly with plain water.

Wearing disposable gloves is recommended during reconstitution and when wiping the outer surface of the vials and the table after reconstitution.

Incompatibilities

Cymevene should not be mixed with other i.v. products.

Preparation of Cymevene reconstituted solution

1. Lyophilized Cymevene should be reconstituted by injecting 10 ml of sterile water for injection into the vial.
Do not use bacteriostatic water for injection containing parabens (para-hydroxybenzoates), since these are incompatible with Cymevene sterile powder and may cause precipitation.
2. The vial should be gently swirl in order to ensure complete wetting of the product. Continue swirling until a clear reconstituted solution is obtained.
Reconstituted solution should be inspected for particulate matter prior to proceeding with admixture preparation.
3. From a microbiological point of view, the reconstituted solution should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user.

Preparation of Cymevene infusion solution

Based on patient weight the appropriate calculated dose volume should be removed from the Cymevene vial (concentration 50 mg/ml) and added to an acceptable infusion fluid. Normal saline, dextrose 5% in water, Ringer’s or lactated Ringer’s solution are determined chemically or physically compatible with Cymevene. Infusion concentrations greater than 10 mg/ml are not recommended.

From a microbiological perspective, because Cymevene is reconstituted with non-bacteriostatic sterile water, the infusion solution should be used as soon as possible. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and should not be longer than 24 hours at 2°c to 8°c.

Disposal of unused/ expired medicines

The release of pharmaceuticals in the environment should be minimized. Medicines should not be disposed of via wastewater and disposal through household waste should be avoided.

The following points should be strictly adhered to regarding the use and disposal of syringes and other medicinal sharps:

- Needles and syringes should never be reused.
- Place all used needles and syringes into a sharps container (puncture-proof disposable container).
- Dispose of the full container and of the administration system according to local requirements.

5. PACKS	
Vials 500 mg	1

Medicine: keep out of reach of children

Current at Dec 2021

CHEPLAPHARM Arzneimittel GmbH, Greifswald, Germany